sacubitril valsartan
Selected indexed studies
- Sacubitril/Valsartan: Neprilysin Inhibition 5 Years After PARADIGM-HF. (JACC Heart Fail, 2020) [PMID:33004114]
- Sacubitril/valsartan: A practical guide. (Rev Port Cardiol (Engl Ed), 2019) [PMID:30679005]
- Sacubitril/valsartan: An antiarrhythmic drug? (J Cardiovasc Electrophysiol, 2022) [PMID:36069136]
_Worker-drafted node — pending editorial review._
Connections
sacubitril valsartan is a side effect of
Sources
- Sacubitril/Valsartan: Neprilysin Inhibition 5 Years After PARADIGM-HF. (2020) pubmed
- Sacubitril/valsartan: beyond natriuretic peptides. (2017) pubmed
- Sacubitril/valsartan-induced liver injury: A case report and literature review. (2023) pubmed
- Sacubitril/valsartan: A practical guide. (2019) pubmed
- Sacubitril/valsartan: An antiarrhythmic drug? (2022) pubmed
- Efficacy of Sacubitril/Valsartan in Hypertension. (2022) pubmed
- Is Sacubitril/Valsartan Antifibrotic? (2019) pubmed
- Sacubitril/Valsartan-induced Angioedema. (2024) pubmed
- Effect of sacubitril-valsartan on the incidence of atrial fibrillation: A meta-analysis. (2023) pubmed
- Sacubitril/valsartan therapeutic strategy in HFpEF: Clinical insights and perspectives. (2019) pubmed